BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 2295906)

  • 1. Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndrome.
    Kohn EC; Steis RG; Sausville EA; Veach SR; Stocker JL; Phelps R; Franco S; Longo DL; Bunn PA; Ihde DC
    J Clin Oncol; 1990 Jan; 8(1):155-60. PubMed ID: 2295906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome.
    Foss FM; Ihde DC; Linnoila IR; Fischmann AB; Schechter GP; Cotelingam JD; Steinberg SM; Ghosh BC; Stocker JL; Bastian A
    J Clin Oncol; 1994 Oct; 12(10):2051-9. PubMed ID: 7931473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome.
    Foss FM; Ihde DC; Breneman DL; Phelps RM; Fischmann AB; Schechter GP; Linnoila I; Breneman JC; Cotelingam JD; Ghosh BC
    J Clin Oncol; 1992 Dec; 10(12):1907-13. PubMed ID: 1453206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome.
    Kuzel TM; Roenigk HH; Samuelson E; Herrmann JJ; Hurria A; Rademaker AW; Rosen ST
    J Clin Oncol; 1995 Jan; 13(1):257-63. PubMed ID: 7799028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant leukocyte interferon alfa-2a in the treatment of mycosis fungoides.
    Simoni R; Cavalieri R; Coppola G; Ricciotti L; De Pità O; Criscuolo D; Covelli A; Papa G; Mandelli F
    J Biol Regul Homeost Agents; 1987; 1(2):93-9. PubMed ID: 3504088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas.
    Bunn PA; Ihde DC; Foon KA
    Cancer; 1986 Apr; 57(8 Suppl):1689-95. PubMed ID: 3485012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon and low dose methotrexate improve outcome in refractory mycosis fungoides/Sézary syndrome.
    Avilés A; Nambo MJ; Neri N; Castañeda C; Cleto S; Gonzalez M; Huerta-Guzmán J
    Cancer Biother Radiopharm; 2007 Dec; 22(6):836-40. PubMed ID: 18158775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA.
    Mostow EN; Neckel SL; Oberhelman L; Anderson TF; Cooper KD
    Arch Dermatol; 1993 Jun; 129(6):747-52. PubMed ID: 8507078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study.
    Querfeld C; Thompson JA; Taylor MH; DeSimone JA; Zain JM; Shustov AR; Johns C; McCann S; Lin GHY; Petrova PS; Uger RA; Molloy N; Shou Y; Akilov OE
    Lancet Haematol; 2021 Nov; 8(11):e808-e817. PubMed ID: 34627593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sezary syndrome.
    Sanli H; Akay BN; Anadolu R; Ozcan M; Saral S; Akyol A
    J Drugs Dermatol; 2011 Apr; 10(4):403-8. PubMed ID: 21455551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I trial of interferon-alpha-2a plus cyclophosphamide, vincristine, prednisone, and doxorubicin.
    Schiller JH; Hawkins MJ; O'Connell MJ; Sielaff K; Borden EC
    J Biol Response Mod; 1989 Jun; 8(3):252-61. PubMed ID: 2746297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon alpha-2a in cutaneous T-cell lymphoma.
    Vegna ML; Papa G; Defazio D; Pisani F; Coppola G; De Pità O; Puddu P; Ferranti G; Simoni R; Mandelli F
    Eur J Haematol Suppl; 1990; 52():32-5. PubMed ID: 2279544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up in 51 patients with mycosis fungoides and Sézary syndrome treated by interferon-alfa.
    Jumbou O; N'Guyen JM; Tessier MH; Legoux B; Dréno B
    Br J Dermatol; 1999 Mar; 140(3):427-31. PubMed ID: 10233261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma.
    Roenigk HH; Kuzel TM; Skoutelis AP; Springer E; Yu G; Caro W; Gilyon K; Variakojis D; Kaul K; Bunn PA
    J Invest Dermatol; 1990 Dec; 95(6 Suppl):198S-205S. PubMed ID: 2258636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of advanced mycosis fungoides and Sézary syndrome with continuous infusions of methotrexate followed by fluorouracil and leucovorin rescue.
    Schappell DL; Alper JC; McDonald CJ
    Arch Dermatol; 1995 Mar; 131(3):307-13. PubMed ID: 7887660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pentostatin (Nipent) in T-cell malignancies. Leukemia Cooperative Group and the European Organization for Research and Treatment of Cancer.
    Ho AD; Suciu S; Stryckmans P; De Cataldo F; Willemze R; Thaler J; Peetermans M; Döhner H; Solbu G; Dardenne M; Zittoun R
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):52-7. PubMed ID: 10877053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.
    Khodadoust MS; Rook AH; Porcu P; Foss F; Moskowitz AJ; Shustov A; Shanbhag S; Sokol L; Fling SP; Ramchurren N; Pierce R; Davis A; Shine R; Li S; Fong S; Kim J; Yang Y; Blumenschein WM; Yearley JH; Das B; Patidar R; Datta V; Cantu E; McCutcheon JN; Karlovich C; Williams PM; Subrahmanyam PB; Maecker HT; Horwitz SM; Sharon E; Kohrt HE; Cheever MA; Kim YH
    J Clin Oncol; 2020 Jan; 38(1):20-28. PubMed ID: 31532724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial.
    Wollina U; Looks A; Meyer J; Knopf B; Koch HJ; Liebold K; Hipler UC
    J Am Acad Dermatol; 2001 Feb; 44(2):253-60. PubMed ID: 11174383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy.
    Budd GT; Murthy S; Finke J; Sergi J; Gibson V; Medendorp S; Barna B; Boyett J; Bukowski RM
    J Clin Oncol; 1992 May; 10(5):804-9. PubMed ID: 1569452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.